EClinicalMedicine · Nov 18, 2026
Incidence of cervical cancer in hrHPV-positive patients with low-grade cytological abnormalities: a Dutch nationwide cohort study
By van de Kam L, van Cooten V, Piera E et al.
Background The Dutch cervical cancer screening program uses primary high-risk human papillomavirus (hrHPV) testing, with cytology triage, and referral for colposcopy for all hrHPV-positive women with cytological abnormalities. However, most low-grade abnormalities regress spontaneously, raising concerns regarding overtreatment and unnecessary pressure on the healthcare system. This study aimed to assess the incidence of cervical cancer among hrHPV-positive women with low-grade cytological abnormalities compared with repeated negative for intraepithelial lesion of malignancy (NILM) cytology results, to explore whether these findings support further evaluation of risk-based follow-up strategies. Methods We conducted a retrospective cohort study including women who participated in the Dutch population-based cervical cancer screening program between January 1, 2017, and December 31, 2018. The inclusion period was chosen to align with the initial implementation phase of the revised Dutch screening program, which transitioned in 2017 from cytology-based to primary hrHPV testing. Eligible women were hrHPV-positive with low-grade triage cytology at baseline and hrHPV-positive women with NILM cytology at triage and one-year follow-up. The primary outcome was the five-year cumulative incidence of cervical cancer. This follow-up period corresponds to the interval used in the Dutch national cervical cancer screening program, incorporating the subsequent routine screening round after the baseline hrHPV-positive test. Adjusted analyses were not performed since relevant potential confounders were not available in the nationwide screening registry. This study is registered on ClinicalTrials.gov , ID NCT07259616 . Findings The five-year cumulative incidence of cervical cancer of 22,891 hrHPV-positive women with low-grade triage cytology was 0.47% (107/22,891; 95% CI 0.39–0.56). Among these women, 18,898 had ≤ cervical intraepithelial neoplasia (CIN) I at baseline colposcopy, their five-year cumulative incidence was 0.25% (47/18,898; 95% CI 0.19–0.33). Women with ≤ CIN I and persistent low-grade cytology at one-year follow-up had a five-year cumulative incidence of 0.13% (16/12,592; 95% CI 0.08–0.20). The five-year cumulative incidence among 23,188 hrHPV-positive women with NILM cytology at triage and one-year follow-up was 0.25% (58/23,188; 95% CI 0.19–0.32). Interpretation HrHPV-positive women with low-grade triage cytology, ≤ CIN I at baseline, and persistent low-grade cytology at one-year follow-up have a low five-year cumulative incidence of cervical cancer, which was numerically similar to that observed among women with persistent NILM cytology within the Dutch screening program. Differences in clinical management between groups may have introduced verification bias, as women with low-grade cytology underwent immediate colposcopic assessment whereas women with persistent NILM cytology did not. Given potential verification bias and residual confounding, these hypothesis-generating findings should be interpreted cautiously and warrant confirmation in studies with longer follow-up and prospective risk stratification. Funding No funding was received.